Management of malignant gastrointestinal stromal tumours

Lancet Oncology

Volumn 3, Issue 11, 2002, Pages 655-664

  Joensuu, Heikki ^a,f   Fletcher, Christopher ^b   Dimitrijevic, Sasa ^c   Silberman, Sandra ^c   Roberts, Peter ^d   Demetri, George ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; MITOMYCIN C; PROTEIN KINASE; PROTEIN KIT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; BLOOD TOXICITY; CARCINOGENESIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM TUMOR; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FACE EDEMA; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HISTOPATHOLOGY; HUMAN; LEG EDEMA; MALIGNANT TRANSFORMATION; MESENCHYMOMA; METASTASIS; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; RNA TRANSLATION; STROMA CELL; TUMOR PROMOTION; TUMOR VOLUME;

EID: 0036846345     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00899-9     Document Type: Review

References (80)

1. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
3. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
4. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-19.
5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
6. Clary BM, DeMatteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8: 290-99.
7. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19: 323-24.
8. Beghini A, Tibiletti M, Roversi G, et al. Germline mutation in the juxtamembrane domain of the KIT gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92: 657-62.
9. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120: 210-15.
10. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999; 74: 543-52.
11. Ishida T, Wada I, Horiuchi H, et al. Multiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Reclinghausen's disease). Pathol Int 1996; 46: 689-95.
12. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Am J Surg Pathol 1999; 23: 82-87.
13. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001; 8: 252-61.
14. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-12.
15. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293-301.
16. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-59.
17. Catena F, Pasqualine E, Campione O. Gastrointestinal stromal tumors: experience of an emergency surgery department. Dig Surg 2000; 17: 503-07.
18. Rudolph P, Gloeckner K, Parwaresch R, et al. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 1998; 29: 791-800.
19. Plaat BEC, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-20.
20. Fong Y, Coit DG, Woodruff JM, et al. Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217: 72-77.
21. Mudan SS, Conlon KC, Woodruff JM, et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000; 88: 66-74.
22. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours: recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-20.
23. Lee JR, Joshi V, Griffin JW Jr, et al. Gastrointestinal autonomic nerve tumor: immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001; 25: 979-87.
24. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998; 152: 1259-69.
25. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
26. Hornick JL, Fletcher CDM. Immunohistochemical staining for KIT (CD 117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188-93.
27. Lecoin L, Gabella G, Le Douarin N. Origin of the c-kit positive intestinal cells in the avian bowel. Development 1996; 122: 725-33.
28. Sakurai S, Fukusawa T, Chong J-M, et al. Embryonic form of smooth muscle myosin heavy chain (Seenb/MCH-B) in gastrointestinal stromal tumor and intestitial cells of Cajal. Am J Pathol 1999; 154: 23-28.
29. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors/GISTs in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109-18.
30. Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 77-85.
31. Sakurai S, Hishima T, Takazawa Y, et al. Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol Int 2001; 51: 524-31.
32. Vanderwinden JM, Rumessen JJ, De Laet MH, et al. CD34 immunoreactivity and interstitial cells of Cajal in the human and mouse gastrointestinal tract. Cell Tissue Res 2000; 302: 145-53.
33. Chak A, Canto MI, Rosch T, et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc 1997; 45: 468-73.
34. Wieczorek TJ, Faquin WC, Rubin BP, et al. Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma. Cancer 2001; 93: 276-87.
35. Bonavina L, Segalin A, Rosati R, et al. Surgical therapy of esophageal leiomyoma. J Am Coll Surg 1995; 181: 257-62.
36. Sanders L, Silverman M, Rossi R, et al. Gastric smooth muscle tumors: diagnostic dilemmas and factors affecting outcome. World J Surg 1996; 20: 992-95.
37. Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83.
38. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992; 215: 68-77.
39. Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors ofthe gastrointestinal tract: analysis of prognostic factors. Surgery 1996; 119: 171-77.
40. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
41. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995; 2: 26-31.
42. Evans HL. Smooth muscle tumors of the gastrointestinal tract: a study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56: 2242-50.
43. Dougherty MJ, Compton C, Talbert M, et al. Sarcomas of the gastrointestinal tract: separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg 1991; 214: 569-74.
44. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-95.
45. Spritz RA, Strunk KM, Lee ST, et al. A YAC contig spaning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 1994; 22: 431-36.
46. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1988; 6: 3341-51.
47. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345-64.
48. Weiler SR, Mou S, DeBerry CS, et al. JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood 1996; 87: 3688-93.
49. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor microphthalmia to c-kit signalling in melanocytes. Nature 1998; 391: 298-301.
50. Brizzi MF, Dentelli P, Rosso A, et al. STAT protein recruitment and activation in c-kit deletion mutants. J Biol Chem 1999; 274: 16965-72.
51. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase by ST1571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-32.
52. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma, and seminoma/dysgerminoma in humans: immunohistochemical study of formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424: 135-41.
53. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD 117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998; 28: 498-504.
54. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21.
55. Kitayama H, Tsujimura T, Matsumura I, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 1996; 88: 995-1004.
56. Kitamura Y, Hirota S, Nishida T. Molecular pathology of c-KIT proto-oncogene and development of gastrointestinal stromal tumors. Ann Chir Gynaecol 1998; 87: 282-86.
57. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160: 1567-72.
58. Heinrich MC, Corless CL, Blanke C, et al. KIT mutational status predicts clinical response to ST1571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 2002; 21: 2a (abstr).
59. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53-60.
60. Andersson J, Sjögren H, Meis-Kindblom JM, et al. The complexity of KIT mutations and chromosome rearrangements and their clinical correlations in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160: 15-22.
61. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-95.
62. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001; 193: 505-10.
63. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: a study of 200 cases. Am J Pathol 2000; 157: 1091-95.
64. Fukasawa T, Chong JM, Sakurai S, et al. Allelic loss of 14q and 22q, NF mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 2000; 91: 1241-49.
65. El-Rifai W, Sarlomo-Rikala M, Miettinen M, et al. DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res 1996; 56: 3230-33.
66. Allander SV, Nupponen NN, Ringner M, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 2001; 61: 8624-28.
67. DeMatteo RP, Heinrich MC, El-Rifai W, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after ST1571. Hum Pathol 2002: 33: 466-77.
68. Karakousis CP, Blumenson LE, Canavase G, et al. Surgery for disseminated abdominal sarcoma. Am J Surg 1992; 163: 560-64.
69. Chen H, Pruitt A, Nicol TL, et al. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998; 2: 151-55.
70. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group Study. J Natl Cancer Inst 1991; 83: 926-32.
71. Edmonson J, Marks R, Buckner J, et al. Contrast of response to D-MAP plus sargramostin between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Assoc Cancer Res 1999; 18: (abstr 541).
72. Blair SC, Zalupski MM, Baker LH. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 1994; 17: 480-84.
73. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947-52.
74. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001; 344: 1031-37.
75. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
76. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib mesylate (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-23.
77. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-56.
78. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib mesylate (ST1571) as an anticancer agent for solid tumors. Ann Med 2001; 33: 451-55.
79. Van den Abbeele AD, Badawi RD, Cliché JP, et al. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Assoc Clin Oncol 2002; 21: 403a (abstr).
80. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to ST1571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.